Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis
- Author
- James D. Chalmers, Pierre-Régis Burgel, Charles L. Daley, Anthony De Soyza, Charles S. Haworth, David Mauger, Michael R. Loebinger, Pamela J. McShane, Felix C. Ringshausen, Francesco Blasi, Michal Shteinberg, Kevin Mange, Ariel Teper, Carlos Fernandez, Migdalia Zambrano, Chunpeng Fan, Xiangmin Zhang, Mark L. Metersky, Heidi Schaballie (UGent) , Eva Van Braeckel (UGent) and ASPEN Investigators [missing]
- Organization
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 589.49 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01JXDK9CTR8G9KEWKV3JVYSC7T
- MLA
- Chalmers, James D., et al. “Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.” NEW ENGLAND JOURNAL OF MEDICINE, vol. 392, no. 16, 2025, pp. 1569–81, doi:10.1056/nejmoa2411664.
- APA
- Chalmers, J. D., Burgel, P.-R., Daley, C. L., De Soyza, A., Haworth, C. S., Mauger, D., … [missing], A. I. (2025). Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. NEW ENGLAND JOURNAL OF MEDICINE, 392(16), 1569–1581. https://doi.org/10.1056/nejmoa2411664
- Chicago author-date
- Chalmers, James D., Pierre-Régis Burgel, Charles L. Daley, Anthony De Soyza, Charles S. Haworth, David Mauger, Michael R. Loebinger, et al. 2025. “Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.” NEW ENGLAND JOURNAL OF MEDICINE 392 (16): 1569–81. https://doi.org/10.1056/nejmoa2411664.
- Chicago author-date (all authors)
- Chalmers, James D., Pierre-Régis Burgel, Charles L. Daley, Anthony De Soyza, Charles S. Haworth, David Mauger, Michael R. Loebinger, Pamela J. McShane, Felix C. Ringshausen, Francesco Blasi, Michal Shteinberg, Kevin Mange, Ariel Teper, Carlos Fernandez, Migdalia Zambrano, Chunpeng Fan, Xiangmin Zhang, Mark L. Metersky, Heidi Schaballie, Eva Van Braeckel, and ASPEN Investigators [missing]. 2025. “Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.” NEW ENGLAND JOURNAL OF MEDICINE 392 (16): 1569–1581. doi:10.1056/nejmoa2411664.
- Vancouver
- 1.Chalmers JD, Burgel P-R, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. NEW ENGLAND JOURNAL OF MEDICINE. 2025;392(16):1569–81.
- IEEE
- [1]J. D. Chalmers et al., “Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis,” NEW ENGLAND JOURNAL OF MEDICINE, vol. 392, no. 16, pp. 1569–1581, 2025.
@article{01JXDK9CTR8G9KEWKV3JVYSC7T,
author = {{Chalmers, James D. and Burgel, Pierre-Régis and Daley, Charles L. and De Soyza, Anthony and Haworth, Charles S. and Mauger, David and Loebinger, Michael R. and McShane, Pamela J. and Ringshausen, Felix C. and Blasi, Francesco and Shteinberg, Michal and Mange, Kevin and Teper, Ariel and Fernandez, Carlos and Zambrano, Migdalia and Fan, Chunpeng and Zhang, Xiangmin and Metersky, Mark L. and Schaballie, Heidi and Van Braeckel, Eva and [missing], ASPEN Investigators}},
issn = {{0028-4793}},
journal = {{NEW ENGLAND JOURNAL OF MEDICINE}},
language = {{eng}},
number = {{16}},
pages = {{1569--1581}},
title = {{Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis}},
url = {{http://doi.org/10.1056/nejmoa2411664}},
volume = {{392}},
year = {{2025}},
}
- Altmetric
- View in Altmetric